Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).
Shin
Juyoung
J
Catholic Hematopoietic Stem Cell Transplantation Center, Catholic University of Korea, Seoul, Korea.
Kim
Myungshin
M
Kim
Dae-Bum
DB
Yeom
Ju-Ok
JO
Lee
Hyo-Jin
HJ
Cho
Seok-Goo
SG
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D002881:Chromosomes, Human, Pair 12; D002895:Chromosomes, Human, Pair 5; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014178:Translocation, Genetic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate